Next Article in Journal
Molecular Interactions and Protein-Induced DNA Hairpin in the Transcriptional Control of Bacteriophage Ø29 DNA
Next Article in Special Issue
Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery
Previous Article in Journal
Astaxanthin Improves Stem Cell Potency via an Increase in the Proliferation of Neural Progenitor Cells
Previous Article in Special Issue
Lewis (y) Antigen Overexpression Increases the Expression of MMP-2 and MMP-9 and Invasion of Human Ovarian Cancer Cells
Article Menu

Export Article

Open AccessArticle

Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma

Department of Pathology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
Department of Pathology, National Taiwan University Hospital, and College of Medicine, Taipei, Taiwan
Department of Obstetrics and Gynecology, the University of Tokyo, Tokyo, Japan
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2010, 11(12), 5120-5128;
Received: 1 December 2010 / Revised: 8 December 2010 / Accepted: 8 December 2010 / Published: 13 December 2010
(This article belongs to the Special Issue Cancer Molecules in Ovarian Cancer)
PDF [237 KB, uploaded 19 June 2014]


Recent genome-wide analysis has demonstrated that somatic mutations in ARID1A (BAF250) are the most common molecular genetic changes in ovarian clear cell carcinoma (OCCC). ARID1A mutations, which occur in approximately half of OCCC cases, lead to deletion of the encoded protein and inactivation of the putative tumor suppressor. In this study, we determined the significance of loss of ARID1A immunoreactivity with respect to several clinicopathological features in a total of 149 OCCCs. First, we demonstrated that ARID1A immunohistochemistry showed concordance with the mutational status in 91% of cases with 100% sensitivity and 66% specificity. Specifically, among 12 OCCC cases for which ARIDA mutational status was known, ARIDIA immunoreactivity was undetectable in all 9 cases harboring ARID1A mutations and was undetectable in one of 3 cases with wild-type ARID1A. With respect to the entire cohort, ARID1A immunoreactivity was undetectable in 88 (59%) of 149 OCCCs. There was no significant difference between ARID1A negative and positive cases in terms of histopathologic features, age, clinical stage, or overall survival. In conclusion, this study provides further evidence that mutations in ARID1A resulted in loss of ARID1A protein expression in OCCC, although no significant differences between ARID1A positive and negative cases were observed with respect to any clinicopathological features examined. View Full-Text
Keywords: ovarian; ARID1A; pathology ovarian; ARID1A; pathology
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Maeda, D.; Mao, T.-L.; Fukayama, M.; Nakagawa, S.; Yano, T.; Taketani, Y.; Shih, I.-M. Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma. Int. J. Mol. Sci. 2010, 11, 5120-5128.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top